[ad_1]
Illustrative photo (RBC-Ukraine)
Regulatory approval process may be accelerated due to pandemic
The experimental coronavirus vaccine, which has already begun human testing in the United States and Germany, may appear in millions of doses by the end of 2020. RBC-Ukraine reports this with reference to CNN.
BioNTech vaccine company CEO Ugur Shahin said That regulatory approval may be accelerated by a global pandemic.
“The advantage of the vaccine in a pandemic situation is much greater, and therefore the approval or approval of a vaccine in a pandemic situation should follow different rules than we saw in the past,” Shahin said.
He noted that the vaccine has “very encouraging” preclinical data.
“We see a strong response to vaccines even at low doses. And we believe the vaccine is effective, “said Shahin.
According to him, if the vaccine is approved by the regulatory authorities, then the partners are “ready to work as quickly as possible” to deliver it to the population.
Recall previously reported that aUS pharmaceutical giant Pfizer and German biotech company BioNTech have begun testing an experimental human coronavirus vaccine in the United States. Participants in the first stage of the study were healthy people aged 18 to 55.
Furthermore, RBC-Ukraine wrote that according toAmerican resident Donald Trump, a vaccine against the COVID-19 virus will be ready before the end of the year. He said the vaccine would be “sooner rather than later.”
